AU2704395A - Calpain inhibitors for the treatment of neurodegenerative di seases - Google Patents

Calpain inhibitors for the treatment of neurodegenerative di seases

Info

Publication number
AU2704395A
AU2704395A AU27043/95A AU2704395A AU2704395A AU 2704395 A AU2704395 A AU 2704395A AU 27043/95 A AU27043/95 A AU 27043/95A AU 2704395 A AU2704395 A AU 2704395A AU 2704395 A AU2704395 A AU 2704395A
Authority
AU
Australia
Prior art keywords
seases
neurodegenerative
treatment
calpain inhibitors
calpain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU27043/95A
Inventor
Roland E. Dolle
Todd L. Graybill
Alex L. Harris
Matthew S. Miller
Irennegbe K. Osifo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Sanofi Winthrop Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Winthrop Inc filed Critical Sanofi Winthrop Inc
Publication of AU2704395A publication Critical patent/AU2704395A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU27043/95A 1995-06-13 1995-06-13 Calpain inhibitors for the treatment of neurodegenerative di seases Abandoned AU2704395A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002224721A CA2224721A1 (en) 1995-06-13 1995-06-13 Calpain inhibitors for the treatment of neurodegenerative diseases
PCT/US1995/007463 WO1996041638A1 (en) 1995-06-13 1995-06-13 Calpain inhibitors for the treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
AU2704395A true AU2704395A (en) 1997-01-09

Family

ID=4161896

Family Applications (1)

Application Number Title Priority Date Filing Date
AU27043/95A Abandoned AU2704395A (en) 1995-06-13 1995-06-13 Calpain inhibitors for the treatment of neurodegenerative di seases

Country Status (4)

Country Link
EP (1) EP0840614A1 (en)
AU (1) AU2704395A (en)
CA (1) CA2224721A1 (en)
WO (1) WO1996041638A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6134498A (en) * 1997-03-07 1998-09-22 Hoechst Marion Roussel, Inc. Method of treating trauma associated with brain, spinal cord or peripheral nerveinjury using carbobenzyloxy n-protected di- and tripeptide phenylalaninals
DE19718826A1 (en) * 1997-05-05 1998-11-12 Marion S Dr Eckmiller Use of biologically active agents to influence the extracellular space of sensory cells and methods for drug administration control
EP1159260A1 (en) * 1999-03-15 2001-12-05 Axys Pharmaceuticals, Inc. Novel compounds and compositions as protease inhibitors
JP2004523506A (en) 2000-12-22 2004-08-05 アクシス・ファーマシューティカルズ・インコーポレイテッド Novel compounds and compositions as cathepsin inhibitors
US7030116B2 (en) 2000-12-22 2006-04-18 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
DE10105040A1 (en) 2001-02-05 2002-08-14 Tell Pharm Ag Hergiswil Tripeptide derivatives for the treatment of post-lesion diseases of the nervous system
DE10105041A1 (en) 2001-02-05 2002-08-14 Tell Pharm Ag Hergiswil Tripeptides and tripeptide derivatives for the treatment of neurodegenerative diseases
DE10105038B4 (en) 2001-02-05 2005-07-07 Neurotell Ag Tripeptide derivatives for the treatment of postläsional diseases of the nervous system
DE10105039A1 (en) * 2001-02-05 2002-08-08 Tell Pharm Ag Hergiswil Tripeptide derivatives for the treatment of neurodegenerative diseases
WO2003024924A1 (en) 2001-09-14 2003-03-27 Aventis Pharmaceuticals Inc. Novel compounds and compositions as cathepsin inhibitors
IL161950A0 (en) 2001-11-14 2005-11-20 Axys Pharm Inc Oligopeptides and compositions containing them as cathepsin s inhibitors
ES2219187B1 (en) * 2003-05-14 2006-02-16 Consejo Sup. Investig. Cientificas CALPAINE INHIBITORS.
ES2255848B1 (en) 2004-12-16 2007-07-01 Consejo Superior Investig. Cientificas ISOQUINOLINE DERIVATIVES AS CALPAINE INHIBITORS.
CN107090014B (en) 2008-03-26 2023-04-25 诺维信公司 Stabilized liquid enzyme compositions
US8236798B2 (en) 2009-05-07 2012-08-07 Abbott Gmbh & Co. Kg Carboxamide compounds and their use as calpain inhibitors
CN105431546A (en) * 2013-03-15 2016-03-23 里兰斯坦福初级大学理事会 Activity-based probe compounds, compositions, and methods of use
EP3510380B1 (en) 2016-12-23 2023-11-08 The Board of Trustees of the Leland Stanford Junior University Activity-based probe compounds, compositions, and methods of use
CN110678460A (en) 2017-03-30 2020-01-10 里兰斯坦福初级大学理事会 Protease activated contrast agents for in vivo imaging

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56110661A (en) * 1980-02-04 1981-09-01 Ajinomoto Co Inc Preparation of n-benzyloxycarbonyl-l-aspartic acid
US5444042A (en) * 1990-12-28 1995-08-22 Cortex Pharmaceuticals Method of treatment of neurodegeneration with calpain inhibitors
JPH04273826A (en) * 1991-02-27 1992-09-30 Dainippon Ink & Chem Inc Anti-rs viral agent

Also Published As

Publication number Publication date
CA2224721A1 (en) 1996-12-27
EP0840614A1 (en) 1998-05-13
WO1996041638A1 (en) 1996-12-27

Similar Documents

Publication Publication Date Title
AU7168696A (en) Inhibitors of regulatory pathways
AU5750796A (en) System for the treatment of insomnia
AU7419096A (en) Treatment of vegetables
PL327569A1 (en) Promedications of thrombosin inhibitors
PL322549A1 (en) Inhibitors of proteinous farnesiltransferase
AU1301697A (en) Tyrosin-derivate as alpha-v-integrin inhibitors
AU7443496A (en) Treatment of migraine
AU6174696A (en) Inhibitors of phospholipase a2
AU2704395A (en) Calpain inhibitors for the treatment of neurodegenerative di seases
AU2103295A (en) Methods for the treatment of thrombosis
AU6956696A (en) Uses of tfpi inhibitor for treatment of cancer
AUPN271295A0 (en) Method of treatment
AU6253094A (en) Methods for the treatment of osteoporosis
AU6692996A (en) Inhibitors of apoptosis
AU2424895A (en) Substituted spirodienes for the treatment of inflammation
AU4953796A (en) Dipeptide compounds having ahpba structure
AU1865497A (en) Method for the treatment of a liquid
AU2277597A (en) New inhibitors of sh2-mediated processes
AU3187595A (en) Compounds for the treatment of restenosis
AU6927894A (en) 4-amidinophenylsulphonamides for the treatment of thrombo-embolitic conditions
AU6049796A (en) Lysyloxidase inhibitors
AU7214396A (en) Creatine for the protection of neural tissue
AU7506496A (en) Intimal thickening inhibitory agent
AU5825896A (en) Well inhibition
AU5473694A (en) Nitrosamine inhibition